What’s inside
View ResearchExplore how allergen-specific immunotherapy (AIT) impacts the course of COVID-19 in patients with allergic rhinitis (AR). This study compares SARS-CoV-2 infection rates, hospitalization, and pneumonia between AR patients receiving AIT and those not receiving AIT. Results indicate no significant differences in COVID-19 outcomes, suggesting AIT does not increase SARS-CoV-2 risk, and that female gender may reduce the risk of SARS-CoV-2 positivity.
COVID-19 in Allergic Rhinitis Patients on Immunotherapy
Study examines COVID-19 progression in allergic rhinitis patients receiving allergen-specific immunotherapy (AIT).
Prevalence of COVID-19 in Allergic Rhinitis
Analysis of SARS-CoV-2 infection rates among allergic rhinitis patients with and without AIT.
Hospitalization Rates in Allergic Rhinitis During COVID-19
Study compares hospitalization rates due to COVID-19 in allergic rhinitis patients undergoing AIT and those not receiving AIT.
Risk Factors for COVID-19 in Allergic Rhinitis Patients
Identifying potential risk factors for SARS-CoV-2 positivity in allergic rhinitis patients.
Gender Differences in COVID-19 Risk for Allergic Rhinitis
Study finds female gender decreases risk for SARS-CoV-2 positivity in allergic rhinitis patients.
Immunotherapy and COVID-19 Severity in Allergic Rhinitis
Allergen-specific immunotherapy does not increase COVID-19 severity in allergic rhinitis patients.
.svg)
.jpg)
.webp)
